Jin Medical International (ZJYL) Common Equity (2022 - 2025)

Jin Medical International's Common Equity history runs 4 years deep, the most recent figure standing at $29.6 million for Q3 2025.

• In Q3 2025, Common Equity rose 3.8% year-over-year to $29.6 million; the TTM figure through Sep 2025 stood at $29.6 million (up 3.8% YoY), while the FY2025 annual figure was $29.6 million, up 3.8% from the prior year.
• Common Equity came in at $29.6 million for Q3 2025 at Jin Medical International, up from $27.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $29.6 million in Q3 2025 to a low of $15.2 million in Q3 2022.
• A 4-year average of $25.0 million and a median of $26.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 57.39% in 2023 and increased 3.8% in 2025, its largest moves.
• Jin Medical International's Common Equity stood at $15.2 million in 2022, then surged by 57.39% to $24.0 million in 2023, then gained by 19.07% to $28.6 million in 2024, then grew by 3.8% to $29.6 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $29.6 million, $27.8 million, and $28.6 million for Q3 2025, Q1 2025, and Q3 2024 respectively.

Peer Comparison